8-K: Silo Pharma Secures Exclusive Option for Neuroinflammatory Disease IP from University of Maryland

Silo Pharma has entered into a new agreement with the University of Maryland, Baltimore, terminating a prior license and granting an exclusive evaluation license and option for intellectual property related to central nervous system-homing peptides for neuroinflammatory disease.

Summary

• Silo Pharma, Inc. (the Company) and the University of Maryland, Baltimore (UMB) entered into a Termination, Commercial Evaluation License, and Option Agreement on July 8, 2025.
• This new agreement terminates the Master License Agreement (MLA) that was previously in effect since February 12, 2021.
• Silo Pharma receives an exclusive, non-transferable evaluation license for intellectual property concerning central nervous system-homing peptides (the Invention and Patent Rights).
• The Company also gains an exclusive option to negotiate a new exclusive commercial license for the therapeutic treatment of neuroinflammatory disease worldwide.
• To exercise the option, Silo Pharma must provide written notice, submit an acceptable commercialization plan to UMB, and pay a $1,000 option fee, which is creditable against future patent expenses if a commercial license is executed.
• The evaluation license is for non-clinical internal research purposes only, aimed at evaluating the Invention, potential products, and the viability of a commercial license.
• The agreement is effective as of July 8, 2025, and is set to expire on March 31, 2026, unless a new definitive license agreement is executed upon option exercise or it is terminated earlier.
• Any intellectual property derived by Silo Pharma from the Invention during the agreement term must be assigned to UMB and will be included in the commercial license if the option is exercised.

Sentiment

Score: 6

Explanation: The agreement provides a clear path for Silo Pharma to potentially commercialize valuable intellectual property in neuroinflammatory disease, which is a positive strategic step. However, it is an early-stage agreement with significant disclaimers and no guaranteed commercial license, and the company bears all development risk. The nominal option fee is positive, but the future financial obligations (royalties, milestones, patent expenses) are not yet defined. The assignment of derived IP to the University unless the option is exercised is a notable limitation.

Positives

• Secures an exclusive option for a potentially valuable intellectual property in the therapeutic treatment of neuroinflammatory disease worldwide.
• The option fee is a nominal $1,000, which is creditable against future patent expenses, indicating a low initial cost for securing the potential commercial rights.
• The agreement provides an exclusive evaluation license, allowing Silo Pharma to conduct internal research and assess the commercial potential of the Invention before committing to a full commercial license.
• The termination of the previous Master License Agreement (MLA) and entry into this new agreement suggests a restructuring that may be more favorable or better aligned with current strategic goals.

Negatives

• The current license is only for evaluation purposes and does not grant commercial rights; a separate negotiation is required for a full commercial license.
• The University of Maryland, Baltimore retains significant rights, including the ability to license the Invention to third parties for research and commercial purposes outside of the Option Field.
• Any intellectual property derived by Silo Pharma from the Invention during the evaluation period must be assigned to the University, limiting the Company's direct ownership of new developments based on this IP unless the option is exercised.
• The University disclaims all express or implied warranties regarding the Invention, Patent Rights, or Confidential Information, including reliability, completeness, accuracy, infringement, performance, safety, effectiveness, or commercial viability, placing all risk on Silo Pharma.
• The U.S. Government retains certain rights, including the ability to grant licenses to others or practice the invention itself, which could impact the exclusivity or value of a future commercial license.

Risks

• Commercialization Risk: There is no guarantee that a commercial license will be obtained, as it requires successful negotiation and an acceptable commercialization plan to UMB.
• Intellectual Property Risk: The University disclaims all warranties regarding infringement, meaning Silo Pharma bears the risk of third-party intellectual property claims.
• Development Risk: The Invention and Patent Rights are provided "AS IS," with no guarantees regarding safety, effectiveness, or commercial viability, requiring significant R&D investment and risk from Silo Pharma.
• Government Rights Impact: The U.S. Government retains rights to the Invention under Federal IP Policy, which could lead to non-exclusive licenses or government use, potentially diminishing the value of Silo Pharma's exclusive option.
• Derived IP Loss: If the option is not exercised, any intellectual property derived by Silo Pharma from the Invention during the evaluation period will revert entirely to the University, representing a potential loss of R&D investment.
• Limited Scope of Current License: The current license is strictly for non-clinical internal research and evaluation, with no commercial rights, limiting immediate revenue generation from this IP.

Future Outlook

Silo Pharma has secured an exclusive option to negotiate a royalty-bearing commercial license for the therapeutic treatment of neuroinflammatory disease worldwide, contingent on providing an acceptable commercialization plan and paying a $1,000 option fee. The Company intends to make good faith efforts to evaluate the potential of developing the Invention and Patent Rights into commercial products during the agreement term, which expires March 31, 2026.

Management Comments

• Silo Pharma, Inc. entered into a Termination, Commercial Evaluation License, and Option Agreement with the University of Maryland, Baltimore.
• The Agreement terminates the Master License Agreement dated February 12, 2021, previously in effect between the Company and UMB.
• The Agreement provides the Company with an exclusive, non-transferable evaluation license, as well as an exclusive option to negotiate a new exclusive commercial license, with respect to certain intellectual property related to central nervous system-homing peptides.
• The Company will make good faith efforts to evaluate the potential of developing the Invention and Patent Rights into commercial products.

Industry Context

This agreement positions Silo Pharma to potentially advance its pipeline in neuroinflammatory diseases, a significant area of unmet medical need within the biotechnology and pharmaceutical industry. The focus on central nervous system-homing peptides suggests an innovative approach to drug delivery or targeting, which aligns with broader industry trends towards precision medicine and novel therapeutic modalities. The termination of a prior MLA and the establishment of an evaluation and option agreement indicate a strategic re-evaluation of the intellectual property, common in early-stage drug development where companies seek to optimize their licensing terms and development pathways.

Comparison to Industry Standards

• The structure of an evaluation license followed by an option for a commercial license is a common industry practice for early-stage intellectual property, allowing companies like Silo Pharma to conduct due diligence before committing to larger financial obligations.
• The nominal $1,000 option fee is typical for such early-stage agreements, where the primary commitment is the R&D effort and potential future royalties/milestones rather than upfront payments.
• The inclusion of "march-in" rights and other U.S. Government rights is standard for intellectual property developed with federal funding, as is the requirement for the licensee to comply with Federal IP Policy.
• The broad disclaimers of warranties by the University are standard in academic licensing, shifting the development and commercialization risk entirely to the licensee, Silo Pharma.
• The requirement for Silo Pharma to assign Derived IP back to the University, with inclusion in a future commercial license, is a common clause in academic collaborations to ensure the originating institution retains rights to improvements based on its foundational IP.

Stakeholder Impact

• Shareholders: Potential for long-term value creation if the option is exercised and the intellectual property successfully developed into commercial products for neuroinflammatory disease. However, there is no immediate financial impact beyond the nominal option fee, and significant R&D investment and risk remain.
• Employees: Continued or potential future engagement in research and development activities related to central nervous system-homing peptides and neuroinflammatory disease.
• University of Maryland, Baltimore: Continues to benefit from potential future royalties and milestone payments if a commercial license is executed, and retains ownership of the core intellectual property and any derived IP.
• Patients: Potential for new therapeutic treatments for neuroinflammatory diseases in the future, contingent on successful development and commercialization.

Next Steps

• Silo Pharma to make good faith efforts to evaluate the potential of developing the Invention and Patent Rights into commercial products.
• Silo Pharma to decide whether to exercise the exclusive option to negotiate a commercial license by March 31, 2026.
• If the option is exercised, Silo Pharma and UMB will negotiate a Master License Agreement for up to 90 days (or longer by agreement).
• Silo Pharma to submit a final report to UMB summarizing the results of its use of the Invention and/or Patent Rights within 30 days of the agreement's termination or expiration.
• Silo Pharma to cooperate with UMB in the prosecution, filing, and maintenance of any Patent Rights.

Key Dates

Recommendation

Keywords

Silo Pharma, University of Maryland Baltimore, UMB, neuroinflammatory disease, central nervous system-homing peptides, intellectual property, license agreement, option agreement, biotechnology, pharmaceutical, drug development, R&D, patent rights, commercialization, SEC filing, 8-K